3-V Biosciences, Inc. a Menlo Park, California-based biopharmaceutical company dedicated to discovering, developing and commercializing novel antiviral therapeutics that target host cell factors required for viral infection, closed a $20m financing.
Backers include existing investors Kleiner Perkins Caufield & Byers and New Enterprise Associates, which participated equally in the funding.
The company intends to use the capital to advance its novel program targeting a host-factor for the treatment of Hepatitis C virus (HCV), earlier-stage pipeline opportunities and its screening platform.
3-V is led by CEO Merdad V. Parsey, MD, PhD.
FinSMEs
05/01/2012